The going-concern warning and rapid cash burn (0.7 quarters runway) make this a high-risk name. The expanded $50M ATM facility will likely lead to significant dilution. Traders should watch for further equity raises and any FDA meeting outcomes for SkinJect — positive regulatory news could temporarily offset dilution fears, but the fundamental cash position is precarious.
Price Chart
Executive Summary
Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.4M, and disclosed substantial doubt about its ability to continue as a going concern. The company highlighted positive Phase 2 SkinJect data and FDA clearance for Teverelix Phase 2b, but operating expenses rose 69% to $8.6M while revenue remained zero. Post-quarter, it expanded its ATM facility from $15.3M to $50M, signaling ongoing dilution risk.
Key Financial Metrics
Key Facts
- Net loss widened to $9.0M in Q1 2026 from $5.1M in Q1 2025
- Operating expenses increased 69% to $8.6M (R&D $2.7M, G&A $5.9M)
- Cash and equivalents stood at $6.4M as of March 31, 2026
- Substantial doubt exists regarding ability to continue as a going concern
- ATM facility expanded post-quarter from ~$15.3M to $50M
- Raised ~$10M in gross proceeds from ATM and SEPA during Q1
- No revenue reported; clinical-stage company with no approved products
- Positive Phase 2 SkinJect data and FDA clearance for Teverelix Phase 2b noted
- LifeArc royalty rate reduced from ~4% to 2% on Teverelix net sales
Financial Impact
Net loss of $9.0M vs $5.1M YoY; cash burn rate ~$8.6M/quarter; $6.4M cash on hand implies ~0.7 quarters of runway without additional financing
Risk Factors
- Going-concern risk — only $6.4M cash vs $8.6M quarterly burn
- Massive dilution from expanded $50M ATM facility
- No approved products or revenue; all programs are clinical-stage
- Net loss widening 76% YoY signals accelerating cash burn
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295423 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.51 $2.45 | ▼ −2.39% | ▼ −2.95% | $2.45 (−2.39%) |
Oct 16, 2026 11d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 7, 2026 20d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.45 (+2304.32%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.45 (+1437.98%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.45 (−1406.77%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.45 (+1417.97%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.45 (+1336.95%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.45 (+503.45%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.45 (−713.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers